Baseline characteristics of all analyzable subjects
| Characteristics . | Total (n = 90) . | Allo-HCT recipients (n = 57) . | Allo-HCT nonrecipients (n = 25) . | P . |
|---|---|---|---|---|
| Age in years, median (range) | 47.0 (17-71) | 47.0 (19-61) | 57.0 (19-71) | .066 |
| Number of subjects | ||||
| <35 vs ≥35 y | 17 vs 73 | |||
| <45 vs ≥45 y | 38 vs 52 | |||
| <55 vs ≥55 y | 65 vs 25 | |||
| Male:female, n:n (%:%) | 45:45 (50:50) | 28:29 (49:51) | 11:14 (44:56) | .669 |
| Splenomegaly, n (%) | 26 (29) | 17 (30) | 7 (28) | .867 |
| Extramedullary involvement, n (%) | 16 (18) | 12 (21) | 3 (12) | .536 |
| Cerebrospinal fluid, n (%) | 8 (9) | 4 (7) | 3 (12) | |
| Others,* n (%) | 8 (9) | 8 (14) | 0 | |
| Hemogram, PB | ||||
| WBC (×103/μL), median (range) | 25.7 (0.2-547.1) | 20.3 (0.2-379.4) | 51.1 (1.6-547.1) | .134 |
| % Blast, median (range) | 59.0 (0-97.0) | 49.0 (0-97.0) | 73.0 (0-97.0) | .051 |
| Serum laboratory results | ||||
| Creatinine, mg/dL, median (range) | 0.8 (0.3-1.5) | 0.8 (0.4-1.5) | 0.8 (0.5-1.5) | .834 |
| LDH, IU, median (range) | 696.0 (116.0-5468.0) | 716.0 (116.0-5468.0) | 786.0 (269.0-3172.0) | .841 |
| Immunologic phenotype | 1.000 | |||
| ALL, n (%) | 83 (92) | 52 (91) | 23 (92) | |
| Biphenotypic acute leukemia, n (%) | 7 (8) | 5 (9) | 2 (8) | |
| Chromosome type | .652 | |||
| Ph alone, n (%) | 30 (33) | 17 (30) | 10 (40) | |
| Additional type, n (%) | 44 (49) | 28 (49) | 12 (48) | |
| Others, n (%) | 6 (7) | 5 (9) | 1 (4) | |
| No mitosis, n (%) | 7 (8) | 5 (9) | 1 (4) | |
| Unknown, n (%) | 3 (3) | 2 (4) | 1 (4) | |
| BCR-ABL1 transcript type | .492 | |||
| Major, n (%) | 25 (28) | 12 (21) | 7 (28) | |
| Minor, n (%) | 65 (72) | 45 (79) | 18 (72) |
| Characteristics . | Total (n = 90) . | Allo-HCT recipients (n = 57) . | Allo-HCT nonrecipients (n = 25) . | P . |
|---|---|---|---|---|
| Age in years, median (range) | 47.0 (17-71) | 47.0 (19-61) | 57.0 (19-71) | .066 |
| Number of subjects | ||||
| <35 vs ≥35 y | 17 vs 73 | |||
| <45 vs ≥45 y | 38 vs 52 | |||
| <55 vs ≥55 y | 65 vs 25 | |||
| Male:female, n:n (%:%) | 45:45 (50:50) | 28:29 (49:51) | 11:14 (44:56) | .669 |
| Splenomegaly, n (%) | 26 (29) | 17 (30) | 7 (28) | .867 |
| Extramedullary involvement, n (%) | 16 (18) | 12 (21) | 3 (12) | .536 |
| Cerebrospinal fluid, n (%) | 8 (9) | 4 (7) | 3 (12) | |
| Others,* n (%) | 8 (9) | 8 (14) | 0 | |
| Hemogram, PB | ||||
| WBC (×103/μL), median (range) | 25.7 (0.2-547.1) | 20.3 (0.2-379.4) | 51.1 (1.6-547.1) | .134 |
| % Blast, median (range) | 59.0 (0-97.0) | 49.0 (0-97.0) | 73.0 (0-97.0) | .051 |
| Serum laboratory results | ||||
| Creatinine, mg/dL, median (range) | 0.8 (0.3-1.5) | 0.8 (0.4-1.5) | 0.8 (0.5-1.5) | .834 |
| LDH, IU, median (range) | 696.0 (116.0-5468.0) | 716.0 (116.0-5468.0) | 786.0 (269.0-3172.0) | .841 |
| Immunologic phenotype | 1.000 | |||
| ALL, n (%) | 83 (92) | 52 (91) | 23 (92) | |
| Biphenotypic acute leukemia, n (%) | 7 (8) | 5 (9) | 2 (8) | |
| Chromosome type | .652 | |||
| Ph alone, n (%) | 30 (33) | 17 (30) | 10 (40) | |
| Additional type, n (%) | 44 (49) | 28 (49) | 12 (48) | |
| Others, n (%) | 6 (7) | 5 (9) | 1 (4) | |
| No mitosis, n (%) | 7 (8) | 5 (9) | 1 (4) | |
| Unknown, n (%) | 3 (3) | 2 (4) | 1 (4) | |
| BCR-ABL1 transcript type | .492 | |||
| Major, n (%) | 25 (28) | 12 (21) | 7 (28) | |
| Minor, n (%) | 65 (72) | 45 (79) | 18 (72) |
LDH, lactate dehydrogenase; Ph, Philadelphia; WBC, white blood cell.
Skin (n = 1), bone and kidney (n = 1), bone (n = 2), pleura (n = 1), intestine (n = 1), liver (n = 1), and soft tissue mass (n = 1).